Journal of Cancer Therapy

Volume 2, Issue 2 (June 2011)

ISSN Print: 2151-1934   ISSN Online: 2151-1942

Google-based Impact Factor: 0.30  Citations  h5-index & Ranking

Clinical Outcome of Topical Interferon Alpha-2b Cream in Phase II Trial for LSIL/CIN 1 Patients

HTML  Download Download as PDF (Size: 135KB)  PP. 203-208  
DOI: 10.4236/jct.2011.22026    5,537 Downloads   10,387 Views  Citations


Objectives: Interferon alpha-2b possesses variable activity against human papillomavirus (HPV) associated cervical intraepithelial neoplasia (CIN). No topical therapy is currently available for treatment of early stage CIN. We evaluated a new patented drug delivery technology in order to achieve topical efficacy. Methods: Two separate studies were conducted in parallel. IFN002 (treatment group) was an open label study. Twenty patients with Pap IIW, III and IIID (CIN1) were treated with intravaginal application of Interferon alpha-2b cream (5 g, 2 MIU/g) three times a week (alternate days) for 6 weeks with 6 weeks of follow up to determine its effect on cytologic and colposcopic assessment. HPV001 (control group) was a 12 week observational study. Both studies had similar inclusion/exclusion criteria and patient population. Results: In IFN002, 8 of 20 patients (40%) in the ITT population showed resolution of abnormal Pap smear during the 12 weeks following start of treatment (responders). In HPV001, 7 of 21 patients (33.3%) were regressors (p = 0.45, one-sided FET). In the PP population, 7 of 12 (58.3%) patients in IFN002 were regressors com-pared to 7 regressors of 19 patients (36.8%) in HPV001 patients (p = 0.21, one-sided FET). Among patients with Pap IIID, 8 of 14 patients in IFN002 showed resolution of abnormal Pap smear, while 4 of 14 patients resolved in HPV001 (one-sided FET, p = 0.13). Conclusions: Interferon alpha-2b cream (5 g, 2 MIU/g) may be an effective treatment for CIN 1 patients, and future investigation is warranted.

Share and Cite:

R. Kurzeja, G. Böhmer and A. Schneider, "Clinical Outcome of Topical Interferon Alpha-2b Cream in Phase II Trial for LSIL/CIN 1 Patients," Journal of Cancer Therapy, Vol. 2 No. 2, 2011, pp. 203-208. doi: 10.4236/jct.2011.22026.

Cited by

[1] A Snapshot of Transdermal and Topical Drug Delivery Research in Canada
[2] Routine Treatment of Cervical Cytological Cell Changes: Diagnostic Standard, Prevention and Routine Treatment of Cervical Cytological Cell Changes–An …
[3] Routine Treatment of Cervical Cytological Cell Changes
Geburtshilfe Frauenheilkd, 2016
[4] Perspectives on Using Nanoscale Delivery Systems in Dermatological Treatment
Current Dermatology Reports, 2015
ВП Квашенко, ?К Акимова, КВ Чайка, ГМ Гусейнова�, 2014
[6] Detection of most frequent HPV infection after treatment of CIN and prevention of recurrences with Interferоn-alfa
G Chakalova, G Gancev, 2013
[7] Recent progress in the application of nanotechnology for prevention and treatment of human papillomavirus infection
Therapeutic delivery, 2012

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.